Startups

How Pipeline Organics Aims to Cut Wastewater Treatment Costs

Led by co-founders Andrew Raslan and Keyvan Jodeiri, Pipeline Organics is developing microbial fuel cells to help food and beverage manufacturers treat wastewater and recover energy as electricity.

Updated

November 16, 2026 12:32 PM

Concept visualisation of Pipeline Organics’ planned TankArc wastewater treatment and energy recovery system at a brewery. IMAGE: PIPELINE ORGANICS

A glass of beer or a bottle of soft drink leaves plenty behind before it reaches the shelf. Producing it requires water and electricity, then creates wastewater that manufacturers must pay to treat. For breweries and other food and beverage manufacturers working with tight margins, those bills can leave less money for new equipment, products and people.  

Pipeline Organics, led by Andrew Raslan (commercial) and Dr Keyvan Jodeiri (technology), sees a resource in that waste. The Nottingham-based cleantech startup, Pipeline Organics, is developing microbial fuel cells that treat food and beverage wastewater while generating electricity. The aim is to help factories lower their operating costs by recovering value from a stream they already produce every day.

Founded in August 2021, Pipeline Organics grew out of the University of Nottingham’s Young Entrepreneurs Scheme, YES20. The founding team won its Engineering, Energy and Environment stream before establishing the company. Andrew, now CEO, brought a background in molecular microbiology and antimicrobial research, later moving into project management and commercialization.

Co-founder and chief scientific officer Keyvan Jodeiri brought a different piece of the puzzle. His research explored biofuel cells that could use sugars in blood to generate electricity for medical implants. The team began asking whether related principles could work outside the body, using organic material in industrial wastewater as fuel. Turning that idea into a business meant finding an application where the environmental benefits came with a clear financial incentive.

Food and beverage manufacturing offered that opportunity. Breweries and other food and beverage manufacturers produce wastewater rich in biodegradable organic material such as leftover carbs and fats or dead proteins, making it suitable food for microorganisms. Treating it at the factory also gives the company a more predictable waste stream than the mixture arriving at a general sewage treatment plant.

“What is filthy for you as a manufacturer is food for the bacteria,” Andrew explains.

‍

Illustration of Pipeline Organics’ planned system, using microbial fuel cells to treat industrial wastewater and generate electricity. IMAGE: PIPELINE ORGANICS

‍

The company’s system, TankArc, contains reactors with specially designed, 3D-printed lattices. Microorganisms growing on the anode break down organic material in wastewater, releasing electrons that electrodes capture as electrical current. This reduces the organic pollution load while recovering some of its energy. Reactors can be grouped into racks or, eventually, containers equipped with plumbing, batteries and controls to serve different factory sizes.

Andrew describes the system as being designed to become self-powering, provided its electricity output scales as expected, with surplus energy available for use on site. At the moment, replacing a brewery’s entire electricity supply is beyond the immediate promise, Andrew admits. The more practical proposition is reducing the amount of power a manufacturer needs to buy through site efficiency upgrades, while cutting its wastewater treatment burden.

The treated wastewater would then go into the sewer for further treatment. Since it contains fewer pollutants, manufacturers could pay less in treatment charges or, in some cases, avoid them altogether. Pipeline Organics is also exploring ways to take the process further by working with partners to make water reuse possible. This could allow manufacturers to reuse the treated water for tasks that do not require high-purity water, such as post-production washing, which accounts for a large share of fresh-water use in the industry.

Much of TankArc’s engineering sits in the lattice itself. It needs sufficient surface area for the biological process while allowing wastewater to flow through without clogging. Different waste streams require different designs. Pipeline Organics combines engineering calculations with proprietary AI-assisted algorithms to adapt the geometry for applications such as beer, wine or fruit juice production.

‍

5-litre microbial fuel cell developed by Pipeline Organics. IMAGE: PIPELINE ORGANICS

‍

Andrew sees this design process as a competitive advantage. Once the geometry has been developed, components can be manufactured from the resulting 3D models. The difficult part is knowing how to design a cell that performs in a particular environment.

The company is competing with established wastewater treatment and energy recovery methods. Anaerobic digestion, for example, produces biogas that can subsequently generate heat and electricity. Pipeline Organics is pursuing direct electricity recovery through compact, modular equipment. Its suitability will depend on the site, the wastewater and the savings it can deliver.  

Early brewery trials have helped the team test those assumptions. At Little Ox Brewery, Pipeline Organics used a compact four-reactor system with real wastewater to assess compatibility and electrical output. The trial also provided practical lessons about monitoring, handling and operating equipment around a working production site. The company is working with Castle Rock Brewery in Nottingham as another development partner and have achieved onsite results that are close to commercial readiness.  

These demonstrations represent an early step towards industrial deployment. During our interview, Andrew said Pipeline Organics had begun selling paid feasibility pilots that measure performance using customers’ wastewater under actual operating conditions. Larger reactor racks would be at the next stage, followed by containerised systems for facilities producing much greater volumes of effluent. They expect to deploy full-scale containers in 2027.

Scaling brings another set of challenges. The team is developing repeatable methods for producing conductive electrodes, maintaining wastewater flow and assembling larger systems. Reducing manufacturing costs while maintaining treatment performance is a central part of this work.

‍

Pipeline Organics’ current benchtop prototype of its microbial fuel cell system. IMAGE: PIPELINE ORGANICS

‍

There will also be useful discoveries along the way: Chief Scientific Officer Keyvan says longer-term ambitions include developing the technology for wastewater sensing and exploring how recovered electricity could support electrochemical production of higher-value chemicals. These could open additional applications for the platform, while the immediate priority remains manufacturing and scaling the wastewater treatment system.

The proposed leasing model reflects the focus on customer economics. Manufacturers would rent equipment rather than purchase it upfront, retaining part of the savings after paying Pipeline Organics. Making that arrangement attractive requires dependable treatment, manageable maintenance and savings that hold up over time.  

Andrew’s and Keyvan’s longer-term vision includes a wider portfolio of environmental technologies. For now, the next test is closer to the brewery floor: can the company turn promising small reactors into equipment food and beverage manufacturers can rely on?

“One man’s waste is another man’s raw material if you’re smart about it,” Andrew says. Pipeline Organics is building its business around that possibility, starting with the water left behind by a drink.

Keep Reading

Artificial Intelligence

DeepCyte Raises US$1.5M to Use AI and Single-Cell Analysis to Predict Drug Toxicity

A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.

Updated

August 10, 2026 5:56 PM

Close up of a capsule blister pack. PHOTO: UNSPLASH

DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.

The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.

Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.

DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.

Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.

The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.